SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal DiseasesGlobeNewsWire · 2 days ago
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeekGlobeNewsWire · 3 days ago
SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?Defense World · Oct 7, 2026
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)GlobeNewsWire · Oct 6, 2026
Head-To-Head Survey: Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX)Defense World · Sep 30, 2026
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247GlobeNewsWire · Sep 28, 2026SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.51 | $0.63 | Beat |
| May 11, 2026 | -$0.80 | -$3.36 | Miss |
| Mar 4, 2026 | $1.01 | $2.00 | Beat |
| Nov 5, 2025 | -$1.60 | -$1.36 | Beat |
| Aug 14, 2025 | -$1.52 | -$1.12 | Beat |
| May 16, 2025 | -$1.55 | -$0.88 | Beat |